A neuropeptide YY5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice

被引:66
作者
Ishihara, A
Kanatani, A
Mashiko, S
Tanaka, T
Hidaka, M
Gomori, A
Iwaasa, H
Murai, N
Egashira, S
Murai, T
Mitobe, Y
Matsushita, H
Okamoto, O
Sato, N
Jitsuoka, M
Fukuroda, T
Ohe, T
Guan, XM
MacNeil, DJ
Van der Ploegn, LHT
Nishikibe, M
Ishii, Y
Ihara, M
Fukami, T
机构
[1] Banyu Pharmaceut Co Ltd, Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan
[2] Merck Res Labs, Rahway, NJ 07065 USA
[3] Merck Res Labs, Boston, MA 02115 USA
关键词
antiobesity effect; YSR-deficient mice; receptor occupancy;
D O I
10.1073/pnas.0510320103
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Neuropeptide Y (NPY) is thought to have a major role in the physiological control of energy homeostasis. Among five NPY receptors described, the NPY Y5 receptor (Y5R) is a prime candidate to mediate some of the effects of NPY on energy homeostasis, although its role in physiologically relevant rodent obesity models remains poorly defined. We examined the effect of a potent and highly selective Y5R antagonist in rodent obesity and dietary models. The Y5R antagonist selectively ameliorated diet-induced obesity (DIO) in rodents by suppressing body weight gain and adiposity while improving the DIO-associated hyperinsulinemia. The compound did not affect the body weight of lean mice fed a regular diet or genetically obese leptin receptor-deficient mice or rats, despite similarly high brain Y5R receptor occupancy. The Y5R antagonist acts in a mechanism-based manner, as the compound did not affect DIO of Y5R-deficient mice. These results indicate that Y5R is involved in the regulation and development of DIO and suggest utility for Y5R antagonists in the treatment of obesity.
引用
收藏
页码:7154 / 7158
页数:5
相关论文
共 36 条
[1]  
[Anonymous], 1993, BIOL NEUROPEPTIDE RE, DOI DOI 10.1007/978-1-59259-465-8_11
[2]  
Arner P, 2000, BRIT J NUTR, V83, pS9
[3]   OBESITY AS AN ADAPTATION TO A HIGH-FAT DIET - EVIDENCE FROM A CROSS-SECTIONAL STUDY [J].
ASTRUP, A ;
BUEMANN, B ;
WESTERN, P ;
TOUBRO, S ;
RABEN, A ;
CHRISTENSEN, NJ .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1994, 59 (02) :350-355
[4]   Gut hormone PYY3-36 physiologically inhibits food intake [J].
Batterham, RL ;
Cowley, MA ;
Small, CJ ;
Herzog, H ;
Cohen, MA ;
Dakin, CL ;
Wren, AM ;
Brynes, AE ;
Low, MJ ;
Ghatei, MA ;
Cone, RD ;
Bloom, SR .
NATURE, 2002, 418 (6898) :650-654
[5]   RAPID AND LOCALIZED ALTERATIONS OF NEUROPEPTIDE-Y IN DISCRETE HYPOTHALAMIC NUCLEI WITH FEEDING STATUS [J].
BECK, B ;
JHANWARUNIYAL, M ;
BURLET, A ;
CHAPLEURCHATEAU, M ;
LEIBOWITZ, SF ;
BURLET, C .
BRAIN RESEARCH, 1990, 528 (02) :245-249
[6]   Y-receptor subtypes - How many more? [J].
Blomqvist, AG ;
Herzog, H .
TRENDS IN NEUROSCIENCES, 1997, 20 (07) :294-298
[7]   Hypothalamic obesity: Multiple routes mediated by loss of function in medial cell groups [J].
Choi, S ;
Dallman, MF .
ENDOCRINOLOGY, 1999, 140 (09) :4081-4088
[8]   Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor [J].
Criscione, L ;
Rigollier, P ;
Batzl-Hartmann, C ;
Rüeger, H ;
Stricker-Krongrad, A ;
Wyss, P ;
Brunner, L ;
Whitebread, S ;
Yamaguchi, Y ;
Gerald, C ;
Heurich, RO ;
Walker, MW ;
Chiesi, M ;
Schilling, W ;
Hofbauer, KG ;
Levens, N .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (12) :2136-2145
[9]   Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist [J].
Daniels, AJ ;
Grizzle, MK ;
Wiard, RP ;
Matthews, JE ;
Heyer, D .
REGULATORY PEPTIDES, 2002, 106 (1-3) :47-54
[10]   Reduced food intake in response to CGP 71683A may be due to mechanisms other than NPY Y5 receptor blockade [J].
O Della Zuana ;
M Sadlo ;
M Germain ;
M Félétou ;
S Chamorro ;
F Tisserand ;
C de Montrion ;
JF Boivin ;
J Duhault ;
JA Boutin ;
N Levens .
International Journal of Obesity, 2001, 25 (1) :84-94